Founded in 2022, Integrated Bio plans to use AI to investigate the age-related decline and dysregulation of cellular stress responses which are linked to medical conditions such as neurodegeneration, cancer, diabetes and osteoarthritis.

Integrated Bio focuses on the manipulation of cellular behavior via synthetic biology and optogenetics; the company will gather data on patterns of cellular activity that characterize pathological conditions, and then apply machine learning to identify drug candidates that improve or potentially resolve these conditions. These small-molecule drugs will have been overlooked by traditional methods of research, and have the potential to modulate stress responses in ways that were previously unfeasible.

The newly raised funds will be used to expand Integrated Biosciences drug pipeline and further develop its synthetic biology and AI platforms. The company operates on a multi-asset business model, developing multiple drug candidates that will be advanced by the company or through partnerships. The diversified strategy aims to maximize the potential impact of its discoveries, allowing for faster progress toward clinical testing.

Source: https://agetech.com/integrated-biosciences-raises-17-million